Hair analysis to discriminate voluntary doping vs inadvertent ingestion of the aromatase inhibitor letrozole
Authors:
- 2 December 2018
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 11 (6) , 762-771
Abstract
Letrozole is an aromatase inhibitor, used to treat postmenopausal women with hormone receptor‐positive or unknown advanced breast cancer. It is prohibited in sport because it is used together with androgen anabolizing steroids to avoid their adverse effects. In the case of an adverse analytical finding, it may be important to distinguish between repetitive use due to voluntary administration and occasional use, possibly due to involuntary intake. With the objective to identify the dose capable of producing a positive hair test, and to apply these results to the scenarios of inadvertent letrozole ingestion by an athlete, this study investigates the urinary excretion and incorporation into hair of single doses of letrozole. Seven subjects were recruited for an excretion study of letrozole and its metabolite bis(4‐cyanophenyl) methanol (M1) in urine, after the consumption of 0.62 mg, 1.25 mg, and 2.5 mg of letrozole, and to investigate the incorporation in hair after ingestion of 0.62 mg and 2.5 mg of letrozole. Urine and hair samples were also obtained from two women in chronic therapy. Urinary concentrations of letrozole and its metabolite M1 were lower in subjects administered once with 0.62 mg, 1.25 mg, or 2.5 mg letrozole than in women in regular therapy with 2.5 mg/day. In hair collected after a single dosage, concentrations of 16–60 pg/mg were detected while in women in chronic therapy concentrations were higher than 160 pg/mg all along the hair shaft. Hair analysis turned to be a promising possibility for the discrimination of letrozole repetitive use vs occasional/inadvertent administration.Keywords
This publication has 31 references indexed in Scilit:
- The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancerBreast Cancer Research and Treatment, 2010
- Indirect androgen doping by oestrogen blockade in sportsBritish Journal of Pharmacology, 2008
- The discovery and mechanism of action of letrozoleBreast Cancer Research and Treatment, 2007
- The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancerInternational Journal Of Clinical Practice, 2007
- Identification of the aromatase inhibitor letrozole in urine by gas chromatography/mass spectrometryRapid Communications in Mass Spectrometry, 2005
- Aromatase—A Brief OverviewAnnual Review of Physiology, 2002
- Effect of letrozole on the lipid profile in postmenopausal women with breast cancerEuropean Journal of Cancer, 2001
- Absolute bioavailability of letrozole in healthy postmenopausal womenBiopharmaceutics & Drug Disposition, 1997
- COMPARATIVE BIOAVAILABILITY OF LETROZOLE UNDER FED AND FASTING CONDITIONS IN 12 HEALTHY SUBJECTS AFTER A 2·5 MG SINGLE ORAL ADMINISTRATIONBiopharmaceutics & Drug Disposition, 1997
- High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1996